<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880187</url>
  </required_header>
  <id_info>
    <org_study_id>AXA1125-101</org_study_id>
    <nct_id>NCT04880187</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of AXA1125 in Subjects With Non Cirrhotic, Non Alcoholic Steatohepatitis and Fibrosis (EMMPACT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axcella Health, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axcella Health, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the effects of AXA1125, an orally active mixture of amino acids,&#xD;
      compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis&#xD;
      in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability&#xD;
      of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice&#xD;
      daily, and a liver biopsy will be done at the beginning and end of the 48-week study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in steatohepatitis</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>2-point improvement from baseline to Week 48 in the non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) based on a scale from 0-8 with 0 being no NASH and 8 being the highest score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of NASH without worsening of fibrosis</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>The proportion of subjects with resolution of NASH with no worsening of fibrosis defined as a post-treatment ballooning score of 0 and an inflammation score of 0 or 1 on liver biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of fibrosis by one stage without worsening of NASH</measure>
    <time_frame>Baseline to week 48</time_frame>
    <description>The proportion of subjects who have at least a 1-stage improvement in fibrosis and no worsening of NASH based on liver biopsy 0 being no fibrosis and 4 being the worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of study drug emergent adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in liver stiffness as measured by vibration controlled transient elastography (Fibroscanâ„¢)</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hepatic fat as measured by MRI</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in measures of glucose control as determined by glycated hemoglobin (HbA1c)</measure>
    <time_frame>Baseline to week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">273</enrollment>
  <condition>Non Alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>AXA1125 22.6g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>22.6 g AXA1125 administered orally BID with or without food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AXA1125 33.9g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>33.9 g AXA1125 administered orally BID with or without food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo administered orally BID with or without food</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXA1125</intervention_name>
    <description>AXA1125 administered BID with or without food</description>
    <arm_group_label>AXA1125 22.6g</arm_group_label>
    <arm_group_label>AXA1125 33.9g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo administered BID with or without food</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to participate in the study and provide written informed consent.&#xD;
&#xD;
          -  Male and female adults aged &gt; 18 years.&#xD;
&#xD;
          -  Must have NASH and fibrosis on a liver biopsy sample&#xD;
&#xD;
          -  If a historical liver biopsy is used for Screening, obtained within 6 months prior to&#xD;
             Screening;&#xD;
&#xD;
          -  Subjects may have a diagnosis of T2DM&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of liver disease (other than NAFLD or NASH)&#xD;
&#xD;
          -  History or presence of cirrhosis and/or history or presence of hepatic decompensation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Harrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pinnacle Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Koziel, MD</last_name>
    <phone>(857) 320-3200</phone>
    <email>clinicaltrials@axcellahealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genevieve Long</last_name>
      <phone>210-982-0336</phone>
      <email>glong@summitclinicalresearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Steatosis</keyword>
  <keyword>Lobular inflammation</keyword>
  <keyword>Balloning</keyword>
  <keyword>Liver biopsy</keyword>
  <keyword>Liver fat</keyword>
  <keyword>Liver stiffness</keyword>
  <keyword>NASH</keyword>
  <keyword>Aminio Acids</keyword>
  <keyword>Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

